Spero Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Spero Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.80M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $47.98M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $103.78M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $53.51M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $18.26M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $9.33M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $18.15M | Mar 11, 2021 |
| FY2018 | Dec 31, 2018 | $1.69M | Mar 14, 2019 |
| FY2018 | Sep 30, 2018 | $658.0K | Mar 14, 2019 |
| FY2018 | Jun 30, 2018 | $463.0K | Mar 14, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.59M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $371.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $933.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.50M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $3.07M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $258.0K | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $696.0K | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $172.0K | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $67.0K | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $3.81M | Mar 16, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.57M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($68.57M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $22.81M | Mar 27, 2025 |
| FY2021 | Dec 31, 2021 | ($89.80M) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($78.30M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($60.90M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($41.70M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($13.86M) | Mar 14, 2019 |
| FY2018 | Sep 30, 2017 | ($9.84M) | Mar 14, 2019 |
| FY2018 | Jun 30, 2017 | ($9.17M) | Mar 14, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.31M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($73.36M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $21.48M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($42.20M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($87.97M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($79.11M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($63.22M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($42.81M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($41.73M) | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | ($33.22M) | Mar 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.47M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $96.76M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $51.44M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $47.59M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $64.53M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $67.00M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $65.78M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $33.89M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $32.87M | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $26.33M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.62M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($23.44M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($33.00M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($7.73M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($64.35M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($85.87M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($50.02M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($39.63M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($39.11M) | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | ($28.96M) | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $157.0K | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $314.0K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $2.44M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $27.0K | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $830.0K | Mar 14, 2019 |
| FY2017 | Dec 31, 2015 | $232.0K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.92M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $110.54M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $182.39M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $124.80M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $171.07M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $153.45M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $106.10M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $129.01M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $93.48M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $13.77M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.90M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $64.42M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $75.50M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $48.87M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $82.78M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $21.41M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $31.53M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $13.15M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $8.52M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $7.41M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.02M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $46.12M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $106.89M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $75.93M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $88.29M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $132.04M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $74.57M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $115.50M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $84.60M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($45.44M) | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($451.07M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($459.64M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($391.07M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($413.88M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($367.46M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($277.71M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($199.43M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($138.50M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($96.84M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($45.44M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.27M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $52.89M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $76.33M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $109.11M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $112.58M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $85.21M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $29.73M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $34.08M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $87.29M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $10.32M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 56.41M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 54.59M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 53.00M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 52.46M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 32.39M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 29.26M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 19.19M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 17.21M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 14.37M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |